GOSS vs UTHR

Gossamer Bio (GOSS) remains a high-risk, high-reward biotech opportunity, primarily driven by its lead asset, GB004 (seralutinib), for Pulmonary Arterial Hypertension (PAH). The significant positive Phase 2 TORREY study results, announced in late 2024, substantially de-risked the asset, validating its potential as a first-in-class, oral treatment in a market with high unmet needs. This solidifies ...

United Therapeutics continues to present a compelling long-term narrative driven by its robust pipeline, particularly with the positive Phase 3 results for Ralinepag and Tyvaso nebulized treprostinil, expanding its addressable markets in pulmonary hypertension and idiopathic pulmonary fibrosis. The company maintains a strong balance sheet with healthy cash flow generation. However, achieving a 10x...